Welcome to our dedicated page for Evolent Health SEC filings (Ticker: EVH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Evolent Health filings document the regulatory disclosures of a healthcare services company focused on complex specialty care and value-based care infrastructure. Its 8-K reports cover operating and financial results, material agreements, capital-structure matters, completed subsidiary transactions, and compensation arrangements tied to executive appointments.
Proxy materials disclose annual meeting matters, board oversight, director elections, executive compensation, and governance practices. Other current reports record board and officer transitions, equity incentives, and corporate events affecting Evolent Health, Inc. and its wholly owned subsidiary structure.
Key takeaways from Evolent Health (EVH) Form 4
Chief Financial Officer John Paul Johnson was granted 25,461 Class A restricted stock units (RSUs) on 1 July 2025 under the company’s Amended and Restated 2015 Omnibus Incentive Compensation Plan. The award was made at no cost (Transaction Code “A”) and increases his directly held stake to 309,245 shares.
The RSUs vest on a back-loaded schedule: 34 % on 1 July 2026 and 33 % on each of 1 July 2027 and 1 July 2028. This tranche represents the second portion of the 2025 annual equity cycle; issuance was contingent on shareholder approval of additional plan shares received at the 5 June 2025 annual meeting.
No open-market purchases, derivative transactions or sales were disclosed, and no earnings or cash proceeds are involved. The filing is therefore routine incentive compensation that strengthens executive equity alignment but has minimal direct financial impact on near-term valuation.
Evolent Health (EVH) said on June 19, 2025 that oncology cost trends through May remain below its expectations, and the company reaffirmed full-year 2025 Adjusted EBITDA guidance of $135.0 million to $165.0 million and Q2 2025 Adjusted EBITDA guidance of $33.0 million to $40.0 million. The company stated it cannot meaningfully reconcile this non-GAAP guidance to net income because several significant reconciling items are not presently determinable. Separately, on June 19 the company and EVH LLC entered a Commitment Letter with Ares Management credit funds for an incremental debt facility to provide non-dilutive capital to retire its 2025 Convertible Notes by October 15, 2025 and to fund working capital, with a post-payoff cash target of no more than $125.0 million.